Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea in Primary Progressive Multiple Sclerosis
NCT01103583Phase 3Terminated
- Sponsor
- Sant'Andrea Hospital
- Start
- Jul 2011
- Primary completion
- Dec 2013
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydroxyurea in primary progressive multiple sclerosis (PPMS), sponsored by Sant'Andrea Hospital. Primary endpoint: Safety and tolerability of hydroxyurea at 2 years. Started Jul 2011; status: terminated.
02
Drugs
hydroxyurea
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT01103583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01103583.